Passage BIO, Inc. 8-K

What Happened

• On March 3, 2026, Passage Bio, Inc. (PASG) filed a Form 8-K (Items 2.02 and 7.01) announcing its financial results for the year ended December 31, 2025 and updated its corporate presentation. The company attached a press release with the results (Exhibit 99.1) and the revised corporate presentation (Exhibit 99.2). The filing was signed by Chief Financial Officer Kathleen Borthwick.

Key Details

• Date filed: March 3, 2026.
• Reporting period: Year ended December 31, 2025 (financial results announced).
• Exhibits attached: Press release with results (Exhibit 99.1) and updated corporate presentation (Exhibit 99.2).
• Form includes interactive XBRL cover page (Exhibit 104); signed by CFO Kathleen Borthwick.

Why It Matters

• This 8-K provides Passage Bio’s latest earnings information (revenue, earnings and other year‑end metrics will be in the attached press release) and refreshed investor materials. Investors should review the press release and updated presentation for specifics on revenue, net income/loss, cash position, guidance, and program updates for implications on valuation and near‑term catalysts. Watch for the company’s subsequent filings (e.g., Form 10‑K) or an earnings call for fuller financial detail and management commentary.